19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace

 

 

 

 


powered by centersite dot net
Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Pre-Op 'Brain Games' Might Prevent Post-Op DeliriumDoes Hard Work Help Preserve the Brain?Staying Active as You Age Not a Guarantee Against DementiaSmog Tied to Raised Risk for Parkinson's, Alzheimer's DiseasePoor Brain Blood Flow Might Spur 'Tangles' of Alzheimer'sIs Apathy an Early Sign of Dementia?A-Fib Treatment Reduces Patients' Dementia RiskFall Risk Rises Even in Alzheimer's Early StagesPTSD May Be Tied to Greater Dementia RiskNew Research Links Another Gene to Alzheimer's RiskIs Rural Appalachia a Hotspot for Alzheimer's?Why Are Dementia Patients Getting Risky Psychiatric Drugs?Get Dizzy When Standing Up? It Could Be Risk Factor for DementiaCan Seniors Handle Results of Alzheimer's Risk Tests?More Education May Slow Start of Early-Onset Alzheimer'sUnder 50 and Overweight? Your Odds for Dementia Later May RiseBlood Test Heralds New Era in Alzheimer's Diagnosis9/11 First Responders Have Higher Odds for Alzheimer's: StudyCould the Flu Shot Lower Your Risk for Alzheimer's?Will Your Brain Stay Sharp Into Your 90s? Certain Factors Are KeyResearchers Zero in on Alzheimer's Disease Risk FactorsMany Americans With Dementia Live in Homes With GunsBrain's Iron Stores May Be Key to Alzheimer'sHormones May Explain Greater Prevalence of Alzheimer's in WomenMiddle-Age Obesity Linked to Higher Odds for DementiaCould Crohn's, Colitis Raise Dementia Risk?5 Healthy Steps to Lower Your Odds for Alzheimer'sCOVID-19 Brings New Challenges to Alzheimer's CaregivingAlzheimer's Gene Linked to Severe COVID-19 RiskHealthier Heart, Better Brain in Old AgeAHA News: Hearing Loss and the Connection to Alzheimer's Disease, DementiaBrain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: StudyCertain Gene Might Help Shield At-Risk People From Alzheimer'sHow to Connect With Nursing Home Patients in QuarantineHow to Ease Loved Ones With Alzheimer's Through the PandemicCaring for Dementia Patient During Pandemic? Try These Stress-Busting TipsDirty Air Might Raise Your Odds for DementiaRecovery From Mild Brain Trauma Takes Longer Than Expected: StudyCould Sleep Apnea Put You at Risk for Alzheimer's?Daily Aspirin Won't Stop Dementia, Study FindsStudy Ties Brain Inflammation to Several Types of DementiaHeart Drug Combos Might Also Lower Your Dementia Risk: StudyU.S. Primary Care Docs Unprepared for Surge in Alzheimer's CasesMaria Shriver Sounds the Alarm on Women and Alzheimer'sTraumatic Brain Injuries Raise Risk of Psychiatric Ills in SoldiersGrowing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeTwo Experimental Drugs Disappoint With Inherited Alzheimer'sGene Variant Ups Dementia Risk in Parkinson's Patients: StudyGene Variation May Protect Against Alzheimer's: StudyWhen Dementia Harms Speech, Native Language Matters
Questions and AnswersVideosLinksBook Reviews
Related Topics

Aging & Geriatrics
Memory Problems
Elder Care

Brain Plaques Signal Alzheimer's Even Before Other Symptoms Emerge: Study

HealthDay News
by -- Robert Preidt
Updated: Apr 13th 2020

new article illustration

MONDAY, April 13, 2020 (HealthDay News) -- Even before symptoms develop, the brains of people with early Alzheimer's disease have high levels of amyloid protein plaques, a new study reveals.

Those levels in older adults with no dementia symptoms are associated with a family history of disease, lower scores on thinking/memory tests, and declines in daily mental function.

The first findings from the so-called A4 study funded by the U.S. National Institute on Aging (NIA) were published recently in the journal JAMA Neurology. A4 stands for Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease.

The study -- due for completion in late 2022 -- is an ongoing trial that was launched in 2014. It's investigating whether the drug solanezumab can slow mental decline associated with elevated amyloids if people start taking it before Alzheimer's symptoms emerge.

Amyloid, a hallmark of Alzheimer's, has been the target of experimental treatments in clinical trials involving people who already have symptoms of the disease.

"A major issue for amyloid-targeting Alzheimer's disease clinical trials, and one that is being addressed with the A4 study, is that previous trials may have been intervening too late in the disease process to be effective," said NIA director Dr. Richard Hodes.

"A4 is pioneering in the field because it targets amyloid accumulation in older adults at risk for developing dementia before the onset of symptoms," he noted in a NIA news release.

The researchers used amyloid positron emission tomography (PET) imaging to screen nearly 4,500 older adults for the study. The investigators identified and enrolled more than 1,300 with high amyloid levels in the brain, but no Alzheimer's symptoms.

The study was the first to use PET to identify people with high levels of amyloid but no signs of mental ("cognitive") decline, according to Laurie Ryan, chief of the NIA's Dementias of Aging branch.

"Before the availability of amyloid PET, other amyloid-targeting clinical trials may have been testing therapies in some people who didn't have amyloid," she said in the news release.

Lead author Dr. Reisa Sperling, of the neurology department at Brigham and Women's Hospital in Boston, said screening data for all those who had PET scans is available to other researchers. It may help improve screening and enrollment in other trials designed to prevent Alzheimer's in people without symptoms, she said.

According to Ryan, "A4 demonstrates that prevention trials can enroll high-risk individuals -- people with biomarkers for Alzheimer's who are cognitively normal. Ultimately, precision medicine approaches will be essential."

She predicted that Alzheimer's disease will never have a "one-size-fits-all" treatment. "We're likely to need different treatments, even combinations of therapies, for different individuals based on their risk factors," Ryan explained.

More information

The Alzheimer's Association has more on Alzheimer's disease.